CD274 and non-small cell lung carcinoma: Targeted PD-1 or PD-L1 immune checkpoint inhibitors, whether combined with chemotherapy or as a monotherapy, have gained widespread acceptance as first-line treatment of non-small cell lung cancer (NSCLC) (5).